Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07661940Phase 2Not Yet Recruiting

Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine

Role: collaborator

NCT05135624Phase 1Terminated

SP16 as a Therapeutic for COVID-19 Induced ARDS

Role: lead

NCT04225533Phase 1Completed

SP16 Inflammatory Response Inhibition Trial

Role: lead

NCT03651089Phase 1Completed

SP16 SERPIN-like Peptide Administration in Healthy Individuals

Role: lead

All 4 trials loaded